医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NuGEN Technologies Announces Launch of Fusion Data Analysis Application, Enabling Simplified Fusion Detection and Discovery

2016年08月02日 PM07:00
このエントリーをはてなブックマークに追加


 

SAN CARLOS, Calif.

NuGEN Technologies, Inc. today announced the availability of the Ovation Fusion Detection application, providing a data analysis tool for the Ovation Fusion Target Enrichment System V2 that enables a complete sample-to-analysis workflow for fusion discovery and detection.

The Ovation Fusion Panel Target Enrichment System V2 allows the comprehensive interrogation of multiple, specific genes for RNA sequencing, significantly simplifying fusion detection when compared with standard RNA sequencing approaches. Sequence data generated from this targeted enrichment technology can then be analyzed using the application on the BaseSpace cloud or as a local Linux installation.

Structural chromosome rearrangements resulting in fusion genes are implicated in all types of human cancer, making the discovery and detection of these fusions valuable for both diagnostic and prognostic purposes.

“The Ovation Fusion Detection BaseSpace Application in conjunction with NuGEN’s comprehensive fusion panel provides a simple start to finish workflow,” said Brandon Young, Director at Avera Cancer Institute for Precision Oncology Genomics Laboratory. “This solution helps us to not only identify clinically actionable fusions but also to perform basic research to study how other fusions may be relevant to cancer progression and prognosis in a single assay.”

“A lung adenocarcinoma tumor that was determined to have an ALK rearrangement by clinical SNaPshot Genotyping (multiplex PCR assay) was grown as a patient-derived xenograft model. Using NuGEN’s fusion detection workflow, the tumor was confirmed to have an EML4-ALK fusion after two passages in mice,” said Laura Saunders, PhD, Associate Director of Molecular Biology at AbbVie Stemcentrx.

NuGEN’s products offer rapid and simple workflows for a broad range of next generation DNA and RNA sequencing applications, enabling highly sensitive detection of variants and expression levels from tissues, single cells and liquid biopsies. NuGEN’s products are used by thousands of scientists worldwide and have been cited in over 2,000 peer-reviewed publications.

About NuGEN Technologies, Inc.

Based in San Carlos, CA, NuGEN Technologies, Inc. provides innovative products used to prepare biologic samples for targeted genomic analysis. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries. It has a long history of launching products with market leading specs, including the recent launch of Ovation SoLo RNA Seq System that enables targeted depletion of unwanted transcripts and library construction from single cells, and Ovation Fusion Panel Target Enrichment System that enable detection of gene fusions across 502 genes that are implicated in cancer. To learn more about NuGEN visit www.nugen.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005126/en/

CONTACT

NuGEN Technologies, Inc.
Carol Short, 650-590-3002
media@nugen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果